Companies
Novo Nordisk
driving unprecedented growth through its GLP-1 peptide therapeutics for diabetes and obesity.
- Country
- Denmark
- Ticker
- NVO
peptides
eu
legacy
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | The company funds its capital expenditure and operations through cash flow from operating activities | novonordisk.com · sec.gov |
| Capacity | Novo Nordisk is the world's largest manufacturer of insulin and GLP-1, and is currently undergoing significant capacity expansions globally including API, aseptic, and fill-finish production to meet high demand | globenewswire.com · novonordisk.com |
| Certification | DuraTouch device received the CE mark in all European Union countries | novonordisk.com |
| Regulatory approval | Wegovy pill approved in the US (Dec 2025); Alhemo approved in the US; Ozempic label updated; various approvals for Awiqli and Rybelsus in multiple regions including US, EU, Japan, and China | novonordisk.com · pharmamanufacturing.com · sec.gov |
| Production site | Major production sites include Denmark (Kalundborg, Hillerød, Bagsværd, Gentofte, Odense, Hjørring), USA (Clayton, North Carolina; New Hampshire), France (Chartres), China (Tianjin), Ireland (Athlone), and Brazil (Montes Claros) | novonordisk.com · pharmamanufacturing.com |
| Headcount | More than 69,500 employees globally as of 2025 reporting, following a workforce reduction of around 9,000 positions in 2025 | novonordisk.com |
| Revenue | DKK 309,064 million for the full year 2025 | annualreport.novonordisk.com · sec.gov |
Independent sources: globenewswire.com · pharmamanufacturing.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.